Faropenem Medoxomil

Summary

Faropenem Medoxomil (CHEMBL1257070) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including chronic bronchitis and otitis media.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 397.4 Da · C17H19NO8S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1257070
Name	Faropenem Medoxomil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918218
Molecular formula	C17H19NO8S
Molecular weight	397.4
InChIKey	JQBKWZPHJOEQAO-DVPVEWDBSA-N

SMILES: CC1=C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4

IUPAC name: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

Also known as: A-0026, A0026, Faropenem daloxate, Faropenem medoxomil, Fropenem daloxate, SUN-A0026, faropenem medoxomil, FAROPENEM MEDOXOMIL, FAROPENEM DALOXATE, faropenem-medoxomil, faropenem medoxil

Patent coverage: 12 distinct patent families (19 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic bronchitis	3	MONDO:0005607	EFO:0006505
otitis media	2	MONDO:0005441	EFO:0004992

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00255983	PHASE3	TERMINATED	A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
NCT00276042	PHASE2	COMPLETED	A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).